105 related articles for article (PubMed ID: 10235070)
1. CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma.
Chim CS; Kwong YL; Lie AK; Lee CK; Liang R
Hematol Oncol; 1998 Sep; 16(3):117-23. PubMed ID: 10235070
[TBL] [Abstract][Full Text] [Related]
2. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
[TBL] [Abstract][Full Text] [Related]
3. CEOP-B/VIMB vs. promace-CytaBOM in the treatment of intermediate or high grade non-Hodgkin's lymphoma: A randomised multicenter study of Southern Italy Cooperative Group.
Lorusso V; Palmieri G; Bianco AR; Abate G; Catalano G; De Vita F; Dammacco F; Lauta VM; Lucarelli G; Polimeno G; Mantovani G; D'Aprile M; Marzullo F; De Lena M
Int J Oncol; 2000 Jan; 16(1):149-54. PubMed ID: 10601560
[TBL] [Abstract][Full Text] [Related]
4. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
[TBL] [Abstract][Full Text] [Related]
5. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
Kim JG; Sohn SK; Kim DH; Baek JH; Park TI; Lee KB
J Korean Med Sci; 2004 Dec; 19(6):820-5. PubMed ID: 15608392
[TBL] [Abstract][Full Text] [Related]
7. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP.
Economopoulos T; Dimopoulos MA; Mellou S; Pavlidis N; Samantas E; Nicolaides C; Tsatalas C; Papadopoulos A; Papageogriou E; Papasavvas P; Fountzilas G
Eur J Haematol; 2002 Mar; 68(3):135-43. PubMed ID: 12068793
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin's lymphoma.
Fisher RI
Cancer Chemother Pharmacol; 1997; 40 Suppl():S42-6. PubMed ID: 9272133
[TBL] [Abstract][Full Text] [Related]
11. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
12. Epirubicin (CEOP-Bleo) versus idaurubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies.
Avilés A; Nambo MJ; Talavera A; Garcia EL; Huerta-Guzman J; Díaz Maqueo JC
Anticancer Drugs; 1997 Nov; 8(10):937-42. PubMed ID: 9436636
[TBL] [Abstract][Full Text] [Related]
13. Treatment of aggressive non-Hodgkin's lymphoma with dose-intensified epirubicin in combination of cyclophosphamide, vincristine, and prednisone (CEOP-100): a phase II study.
Basaran M; Bavbek ES; Sakar B; Eralp Y; Alici S; Tas F; Yaman F; Dogan O O; Camlica H; Onat H
Am J Clin Oncol; 2001 Dec; 24(6):570-5. PubMed ID: 11801756
[TBL] [Abstract][Full Text] [Related]
14. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study.
Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
Ann Oncol; 1994; 5 Suppl 2():91-5. PubMed ID: 7515652
[TBL] [Abstract][Full Text] [Related]
15. A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial.
Hertzberg M; Matthews JP; Stone JM; Dubosq MC; Grigg A; Ellis D; Benson W; Browett P; Horvath N; Januszewicz H; Abdi E; Green M; Bonaventura A; Marlton P; Cannell P; Wolf M;
Am J Hematol; 2014 May; 89(5):536-41. PubMed ID: 24481640
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of ProMACE-CytaBOM in previously untreated non-Hodgkin's lymphoma of intermediate- or high-grade histology.
Rossi G; Mariano MR; Arcangeli G; Bonfanti V; Capucci MA; Ferremi P; Marpicati P; Meriggi F; Zaniboni A; Izzi T
Hematol Oncol; 1991; 9(3):147-55. PubMed ID: 1718837
[TBL] [Abstract][Full Text] [Related]
17. Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.
De Lena M; Maiello E; Lorusso V; Brandi M; Calabrese P; Romito S; Mazzei A; Marzullo F
Med Oncol Tumor Pharmacother; 1989; 6(2):163-9. PubMed ID: 2473364
[TBL] [Abstract][Full Text] [Related]
18. [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
Huang HQ; Lin XB; Pan ZH; Bu Q; Gao Y; Wang BF; Cai QQ; Xia ZJ; Xu RH; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):391-5. PubMed ID: 17892140
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized study comparing MEMID with a chop-like regimen in elderly patients with aggressive non-Hodgkin's lymphoma.
Chamorey E; Gressin R; Peyrade F; Rossi JF; Lepeu G; Foussard C; Harrousseau JL; Fabbro M; Richard B; Delwail V; Maisonneuve H; Vilque JP; Thyss A
Oncology; 2005; 69(1):19-26. PubMed ID: 16088231
[TBL] [Abstract][Full Text] [Related]
20. A randomized EPOCH vs. CHOP front-line therapy for aggressive non-Hodgkin's lymphoma patients: long-term results.
Khaled HM; Zekri ZK; Mokhtar N; Ali NM; Darwish T; Elattar I; Gaafar R; Moawad MS
Ann Oncol; 1999 Dec; 10(12):1489-92. PubMed ID: 10643541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
